MYNZ Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -13.14%, SMA50 -29.41%, SMA200 -50.24%). The stock’s 14-day RSI is 40.18 (neutral), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -88.29% below its high and over 34.55% above its low.

Mainz Biomed B.V. has 12.52 million shares outstanding. The public float is 3.46 million shares, elevated short interest at 2.74% of float. This equals 246.77 thousand shares. The short ratio is 0.62 days. Institutional investors hold 15.81% of the float. Insiders own 17.43%.

Mainz Biomed B.V. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.90. This means the shares are trading below this model’s fair value.

Mainz Biomed B.V. (NASDAQ:MYNZ) closed at $3.59 USD, gaining $0.03 (0.84%) from the previous close of $3.56. The stock is currently mid-range between its 52-week high and low $0.55 and $5.34. With a market capitalization of about $14.69 million, Mainz Biomed B.V. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.32). Key stats such as the average daily volume over the past year has been around 554.37 thousand shares, trading with heavier-than-usual volume. Headquartered in Mainz, None, Mainz Biomed B.V. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Guido Baechler, the company employs approximately 19 people and listed since November 05, 2021. Mainz Biomed B.V.

Mainz Biomed B.V. generated EPS of $nan over the past year. Five-year average earnings growth is -52.02%. The latest quarter delivered EPS of -$9.60. The next quarter is forecast at $nan. Next year's EPS is expected at $53.25. Mainz Biomed B.V. earnings surprise history is a mixed track record. The quarter that ended April 08, 2025, missed forecasts by 166.67%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -4.0% in August 27, 2024.

Mainz Biomed B.V. trades at a P/E ratio of -1.17, slightly below the S&P 500 average, with a price-to-sales ratio of 27.35 and a price-to-book ratio of 33.55 reflecting a rich premium to book value. The P/FCF stands at -1.34, also above market averages. Compared to sector medians, Mainz Biomed B.V. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Mainz Biomed B.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected fall of -95.8%, reaching $0.14 by June 15, 2026, with a range of $0.00 to $0.32. 1-Year Outlook: Projected loss of -98.2%, with price at $0.06 by March 17, 2027, within a range of $0.00 to $2.40.

Mainz Biomed B.V. (NASDAQ:MYNZ) shares are flat -1.79% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Mainz Biomed B.V. trading at a premium to the broader market with a P/E of -1.17. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.57, suggesting 307.51% upside.